Dovonex Ointment Ref.[2602] Active ingredients: Calcipotriol

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2011  Publisher: LEO Laboratories Limited Longwick Road Princes Risborough Bucks HP27 9RR UK

Contraindications

Dovonex Ointment is contraindicated in patients with known disorders of calcium metabolism and patients with severe liver and kidney disease. As with other topical preparations, Dovonex Ointment is contra-indicated in patients with hypersensitivity to the active substance or any of the excipients.

Special warnings and precautions for use

Dovonex Ointment should not be used on the face. Patients should be advised to wash their hands after applying the ointment and to avoid inadvertent transfer to other body areas, especially the face.

The risk of hypercalcaemia is minimal when the dosage recommendations are followed. Hypercalcaemia may occur if the maximum weekly dose is exceeded. Care should be exercised in patients with other types of psoriasis, since hypercalcaemia has been reported in patients with generalised pustular or erythrodermic exfoliative psoriasis. However, serum calcium is quickly normalised when treatment is discontinued.

During treatment with Dovonex Ointment physicians are recommended to advise patients to limit or avoid excessive exposure to either natural or artificial sunlight. Topical calcipotriol should be used with UV radiation only if the physician and patient consider that the potential benefits outweigh the potential risks (see section 5.3).

Interaction with other medicinal products and other forms of interaction

There is no experience of concomitant therapy with other antipsoriatic products applied to the same skin area at the same time.

Fertility, pregnancy and lactation

Pregnancy

The safety of the use of calcipotriol during human pregnancy has not been established, and studies in animals have shown reproductive toxicity when calcipotriol was administered orally. Calcipotriol should not be used during pregnancy unless clearly necessary.

Lactation

It is not known whether calcipotriol is excreted in breast milk. A decision on whether to abstain from breast-feeding or to abstain from therapy with Dovonex should be made taking into account the benefit of breast-feeding to the newborn/infant and the benefit of Dovonex therapy to the woman.

Effects on ability to drive and use machines

Calcipotriol has no or negligible influence on the ability to drive and to use machines.

Undesirable effects

Very common >1/10
Common >1/100 and <1/10
Uncommon >1/1,000 and <1/100
Rare >1/10,000 and <1/1,000
Very rare <1/10,000

Approximately 25% of the patients treated with Dovonex Ointment could experience an adverse reaction. These reactions are usually mild.

Immune system disorders

Very rare: allergic reactions (including angioedema).

Metabolism and nutrition disorders

Very rare: hypercalcaemia, hypercalciuria, especially if the total recommended dose is exceeded (see section 4.2).

Skin and subcutaneous tissue disorders

Very common: skin irritation

Common: rash, burning sensation, stinging sensation, dry skin, pruritus, erythema, contact dermatitis including facial and perioral.

Uncommon: psoriasis aggravated, eczema.

Unknown frequency: transient changes in skin pigmentation, transient photosensitivity, urticaria, angioedema, periorbital or face oedema.

Various types of rash reactions such as scaly, erythematous, maculo-papular, pustular, bullous have been reported.

Incompatibilities

Should not be mixed with other medicinal products.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.